Our study shows that TNBC patients have significant expression of claudin-1, and that this expression correlates with invasive phenotype, sentinel lymph node positivity, higher tumour grade, higher clinical and TNM stage, and adverse survival outcome. The gene discussed is CLDN1; the disease is neoplasm.